Attached files
| file | filename |
|---|---|
| EX-10.1 - EXHIBIT 10.1 - LUMOS PHARMA, INC. | nlnk-20170105x8kxex101.htm |
| 8-K - 8-K - LUMOS PHARMA, INC. | nlnk-20170105x8k.htm |
Exhibit 10.2
2017 Salaries, Bonus Targets and Stock Options | ||||||
Name and Title | 2017 Base Salary | Bonus Target* | Stock Options | |||
Charles J. Link, Jr., M.D. | $659,900 | 70% | 326,288 | (2) | ||
Chairman of the Board and Chief Executive and Scientific Officer | ||||||
Nicholas N. Vahanian, M.D. | $574,300 | 50% | 312,500 | (2) | ||
Director, President and Chief Medical Officer | ||||||
John B. Henneman, III | $423,600 | 40% | 137,500 | (2) | ||
Chief Financial Officer | ||||||
Carl Langren | $277,500 | 30% | 37,500 | (1) | ||
Vice President of Finance | ||||||
Brian Wiley | $370,700 | 35% | 75,000 | (1) | ||
Chief Commercial Officer | ||||||
* | Bonus Targets listed as percentage of 2017 Base Salary | |||||
(1 | ) | 100% of the shares represented by the stock option shall vest in 48 equal monthly installments beginning on January 3, 2017. | ||||
(2 | ) | 50% of shares represented by the stock option shall vest in 48 equal monthly installments beginning on January 3, 2017. 50% of the shares represented by the stock option shall vest on the following schedule: (i) 12.50% upon completion of current planned Phase 1 equivalency study of new Indoximod salt formulation with “completion” measured by the last patient enrolled in such study, (ii) 12.50% upon completion of the current planned Phase 1 study of pro-Indoximod new chemical entity with "completion" measured by the last patient enrolled in such study, (iii) 12.50% upon increase of closing share price of the Company’s common stock on the Nasdaq Stock Market by at least 33% above exercise price of the stock options granted on January 3, 2017, when measured over 30 consecutive calendar days (must occur by January 3, 2021 or such shares will be forfeited), and (iv) 12.50% upon increase of closing share price of the Company’s common stock on the Nasdaq Stock Market by at least 50% above the exercise price of the stock options granted on January 3, 2017, when measured over 30 consecutive calendar days (must occur by January 3, 2021 or such shares will be forfeited). | ||||